{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T23:13:00Z","timestamp":1649027580084},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00393-020-00754-x","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:02:58Z","timestamp":1582196578000},"page":"175-185","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapie der Riesenzellarteriitis und Polymyalgia rheumatica"],"prefix":"10.1007","volume":"79","author":[{"given":"L.","family":"Horvath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette\u00a0JC, Falk\u00a0RJ, Bacon\u00a0PA et\u00a0al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1\u201311","journal-title":"Arthritis Rheum"},{"key":"754_CR2","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/rheumatology\/ket440","volume":"53","author":"K Herlyn","year":"2014","unstructured":"Herlyn\u00a0K, Buckert\u00a0F, Gross\u00a0WL et al (2014) Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology 53:882\u2013889","journal-title":"Rheumatology"},{"key":"754_CR3","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/art.24459","volume":"61","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay\u00a0MA, Vazquez-Rodriguez\u00a0TR, Lopez-Diaz\u00a0MJ et al (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61:1454\u20131461","journal-title":"Arthritis Rheum"},{"key":"754_CR4","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco\u00a0C, Singh\u00a0YP, Perel\u00a0P et\u00a0al (2015) 2015 Recommendations for the management of polymyalgia rheumatica: a\u00a0European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74:1799\u20131807","journal-title":"Ann Rheum Dis"},{"key":"754_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00393-018-0476-8","volume":"77","author":"F Buttgereit","year":"2018","unstructured":"Buttgereit\u00a0F, Brabant\u00a0T, Dinges\u00a0H et al (2018) S3-Leitlinien zur Behandlung der Polymyalgia rheumatica: Evidenzbasierte Leitlinien der Deutschen Gesellschaft f\u00fcr Rheumatologie (DGRh), der \u00d6sterreichischen Gesellschaft f\u00fcr Rheumatologie und Rehabilitation (OGR) und der Schweizerischen Gesellschaft f\u00fcr Rheumatologie (SGT) sowie teilnehmender medizinisch-wissenschaftlicher Fachgesellschaften und anderer Organisationen. Z\u00a0Rheumatol 77:429\u2013441","journal-title":"Z Rheumatol"},{"key":"754_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich\u00a0B, Agueda\u00a0A, Monti\u00a0S et\u00a0al (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79:19\u201330.","journal-title":"Ann Rheum Dis"},{"key":"754_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/rheumatology\/kev289","volume":"55","author":"AP Diamantopoulos","year":"2016","unstructured":"Diamantopoulos\u00a0AP, Haugeberg\u00a0G, Lindland\u00a0A et al (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a\u00a0more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology 55:66\u201370","journal-title":"Rheumatology"},{"key":"754_CR8","first-page":"103","volume":"33","author":"P Patil","year":"2015","unstructured":"Patil\u00a0P, Williams\u00a0M, Maw\u00a0WW et\u00a0al (2015) Fast track pathway reduces sight loss in giant cell arteritis: results of a\u00a0longitudinal observational cohort study. Clin Exp Rheumatol 33:103\u2013106","journal-title":"Clin Exp Rheumatol"},{"key":"754_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","volume":"41","author":"MA Gonzalez-Gay","year":"1998","unstructured":"Gonzalez-Gay\u00a0MA, Blanco\u00a0R, Rodriguez-Valverde\u00a0V et al (1998) Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 41:1497\u20131504","journal-title":"Arthritis Rheum"},{"key":"754_CR10","doi-asserted-by":"publisher","first-page":"e000612","DOI":"10.1136\/rmdopen-2017-000612","volume":"4","author":"C Duftner","year":"2018","unstructured":"Duftner\u00a0C, Dejaco\u00a0C, Sepriano\u00a0A et al (2018) Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a\u00a0systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open 4:e612","journal-title":"RMD Open"},{"key":"754_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-209-001003","author":"S Monti","year":"2019","unstructured":"Monti\u00a0S, Agueda\u00a0AF, Luqmani\u00a0R et\u00a0al (2019) Systematic literature review informing the 2018 update of the EULAR recommendations for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-209-001003","journal-title":"RMD Open"},{"key":"754_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/bjo.85.9.1061","volume":"85","author":"CC Chan","year":"2001","unstructured":"Chan\u00a0CC, Paine\u00a0M, O\u2019day\u00a0J (2001) Steroid management in giant cell arteritis. Br J Ophthalmol 85:1061\u20131064","journal-title":"Br J Ophthalmol"},{"key":"754_CR13","first-page":"1484","volume":"27","author":"P Chevalet","year":"2000","unstructured":"Chevalet\u00a0P, Barrier\u00a0JH, Pottier\u00a0P et\u00a0al (2000) A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a\u00a0one year followup study of 164 patients. J\u00a0Rheumatol 27:1484\u20131491","journal-title":"J Rheumatol"},{"key":"754_CR14","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1002\/art.22163","volume":"54","author":"M Mazlumzadeh","year":"2006","unstructured":"Mazlumzadeh\u00a0M, Hunder\u00a0GG, Easley\u00a0KA et al (2006) Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a\u00a0double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54:3310\u20133318","journal-title":"Arthritis Rheum"},{"key":"754_CR15","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","volume":"315","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit\u00a0F, Dejaco\u00a0C, Matteson\u00a0EL et\u00a0al (2016) Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 315:2442\u20132458","journal-title":"JAMA"},{"issue":"8","key":"754_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/art.40876","volume":"71","author":"JH Stone","year":"2019","unstructured":"Stone\u00a0JH, Tuckwell\u00a0K, Dimonaco\u00a0S et al (2019) Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a\u00a0randomized trial of tocilizumab. Arthritis Rheumatol 71(8):1329\u20131338","journal-title":"Arthritis Rheumatol"},{"key":"754_CR17","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl\u00a0C, Bijlsma\u00a0JW, De Wit\u00a0M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75:952\u2013957","journal-title":"Ann Rheum Dis"},{"key":"754_CR18","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3899\/jrheum.141347","volume":"42","author":"TA Kermani","year":"2015","unstructured":"Kermani\u00a0TA, Warrington\u00a0KJ, Cuthbertson\u00a0D et\u00a0al (2015) Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J\u00a0Rheumatol 42:1213\u20131217","journal-title":"J Rheumatol"},{"key":"754_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/rheumatology\/kev348","volume":"55","author":"C Labarca","year":"2016","unstructured":"Labarca\u00a0C, Koster\u00a0MJ, Crowson\u00a0CS et al (2016) Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a\u00a0retrospective cohort study. Rheumatology 55:347\u2013356","journal-title":"Rheumatology"},{"key":"754_CR20","doi-asserted-by":"publisher","first-page":"e3524","DOI":"10.1097\/MD.0000000000003524","volume":"95","author":"G Restuccia","year":"2016","unstructured":"Restuccia\u00a0G, Boiardi\u00a0L, Cavazza\u00a0A et al (2016) Flares in biopsy-proven giant cell arteritis in northern Italy: characteristics and predictors in a\u00a0long-term follow-up study. Medicine 95:e3524","journal-title":"Medicine"},{"key":"754_CR21","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr\u00a0AD, Jover\u00a0JA, Spiera\u00a0RF et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56:2789\u20132797","journal-title":"Arthritis Rheum"},{"key":"754_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone\u00a0JH, Tuckwell\u00a0K, Dimonaco\u00a0S et al (2017) Trial of tocilizumab in giant-cell arteritis. N\u00a0Engl J Med 377:317\u2013328","journal-title":"N Engl J Med"},{"key":"754_CR23","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger\u00a0PM, Adler\u00a0S, Kuchen\u00a0S et al (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a\u00a0phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921\u20131927","journal-title":"Lancet"},{"issue":"S2","key":"754_CR24","first-page":"A145","volume":"78","author":"J Stone","year":"2019","unstructured":"Stone\u00a0J, Bao\u00a0M, Han\u00a0J et al (2019) Long-term outcome of tocilizumab for patients with giant cell arteritis: results from part 2 of the GiACTA trial. Ann Rheum Dis 78(S2):A145","journal-title":"Ann Rheum Dis"},{"key":"754_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford\u00a0CA, Cuthbertson\u00a0D, Ytterberg\u00a0SR et al (2017) A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 69:837\u2013845","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"754_CR26","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1136\/annrheumdis-2019-215585","volume":"78","author":"C Nannini","year":"2019","unstructured":"Nannini\u00a0C, Niccoli\u00a0L, Sestini\u00a0S et al (2019) Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study. Ann Rheum Dis 78(10):1444\u20131446","journal-title":"Ann Rheum Dis"},{"key":"754_CR27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","volume":"77","author":"C Dejaco","year":"2018","unstructured":"Dejaco\u00a0C, Ramiro\u00a0S, Duftner\u00a0C et\u00a0al (2018) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 77:636\u2013643","journal-title":"Ann Rheum Dis"},{"key":"754_CR28","doi-asserted-by":"publisher","first-page":"e000426","DOI":"10.1136\/rmdopen-2016-000426","volume":"3","author":"M Cutolo","year":"2017","unstructured":"Cutolo\u00a0M, Hopp\u00a0M, Liebscher\u00a0S et al (2017) Modified-release prednisone for polymyalgia rheumatica: a\u00a0multicentre, randomised, active-controlled, double-blind, parallel-group study. RMD Open 3:e426","journal-title":"RMD Open"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-020-00754-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T18:49:59Z","timestamp":1613760599000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-020-00754-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00754-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"20 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>L.\u00a0Horvath<\/b>: Finanzielle Interessen: Kongressgeb\u00fchr, Reise\u2011, \u00dcbernachtungskosten: Novartis | Fortbildungskosten, Reise\u2011, \u00dcbernachtungskosten: AbbVie. Nichtfinanzielle Interessen: Angestellte Assistenz\u00e4rztin, Klinik f\u00fcr Innere Medizin, Rheumatologie und Immunologie, Medius Klinik Kirchheim \u2013 Akademisches Lehrkrankenhaus der Universit\u00e4t T\u00fcbingen | Mitgliedschaft: Deutsche Gesellschaft f\u00fcr Rheumatologie. <b>B.\u00a0Hellmich<\/b>: Finanzielle Interessen: Vortragshonorare von: AbbVie, BMS, Celgene, MSD, Novartis, Orgentec, Pfizer, Roche. \u2013 Beratungsleistungen: Boehringer, BMS, Celgene, InflaRx, GSK, Roche. Nichtfinanzielle Interessen: Chefarzt der Klinik f\u00fcr Innere Medizin, Rheumatologie und Immunologie, Medius-Kliniken \u2013 Akademisches Lehrkrankenhaus der Universit\u00e4t T\u00fcbingen, Kirchheim u. Teck | Repr\u00e4sentanz in nationalen und internationalen Gremien: Kongresspr\u00e4sident der Deutschen Gesellschaft f\u00fcr Rheumatologie (DGRh) 2017 (Jahreskongress in Stuttgart) | Vorstandsmitglied im Verband rheumatologischer Akutkliniken (VRA) | Rubrikherausgeber der Zeitschrift f\u00fcr Rheumatologie | Koordinator der Leitliniengruppe \u201eGro\u00dfgef\u00e4\u00dfvaskulitiden\u201c der DGRh | Co-Koordinator der AG \u201eEULAR Recommendations \u201aGro\u00dfgef\u00e4\u00dfvaskulitiden\u2018 der EULAR\u201c (Antragsverfahren) | Mitglied der AG \u201eEULAR Recommendations ANCA-assoziierte Vaskulitiden\u201c der EULAR (Publikation 2016) | Mitglied im wissenschaftlichen Kuratorium der Rheumaakademie der DGRh, Vorsitzender des Zertifizierungsausschusses | Federf\u00fchrend an der Erstellung der EULAR-Recommendations zum Management der Gro\u00dfgef\u00e4\u00dfvaskulitiden beteiligt, Koordination der Erstellung der DGRh-Leitlinie zum Management der Gro\u00dfgef\u00e4\u00dfvaskulitiden.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}